evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract,articles/16/pmid,articles/16/title,articles/16/journal,articles/16/pubDate,articles/16/volume,articles/16/issue,articles/16/pages,articles/16/authors,articles/16/elocationId,articles/16/link,articles/16/reference,articles/16/abstract,articles/17/pmid,articles/17/title,articles/17/journal,articles/17/pubDate,articles/17/volume,articles/17/issue,articles/17/pages,articles/17/authors,articles/17/elocationId,articles/17/link,articles/17/reference,articles/17/abstract
9632,GENE_SUMMARY,,"MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.",,2017-04-14,,2475,MTOR,mechanistic target of rapamycin,True,ENST00000361445,NM_004958.3,FRAP1,RAFT1,FRAP2,FRAP,SKS,RAPT1,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9633,GENE_BACKGROUND,,"The MTOR protein is a serineâ€“threonine kinase that coordinates cell growth, protein synthesis and metabolic signaling (PMID: 22500797, 21157483). MTOR activity is mediated through two distinct multi-protein complexes, mTORC1 and mTORC2 (PMID: 22500797, 21157483) which are composed of common subunits (mTOR, mLST8, DEPTOR) (PMID: 12718876, 19446321) and uniquely defined by specific subunits. mTORC1 is defined by the PRAS40 and RAPTOR subunits (PMID: 12150926, 12150925, 17386266, 17510057), while mTORC2 is defined by RICTOR, mSIN1 and PROTOR1/2 (PMID: 15268862, 15718470, 16919458). The two best characterized downstream targets of mTORC1, S6K and 4EBP1, dictate the rate of protein synthesis, nutrient response and many additional features required for rapid tumor growth (PMID: 15314020). Consequently, inhibition of mTORC1 has been therapeutically exploited across a variety of malignancies. mTORC2 coordinates with PDK1 to phosphorylate and activate AKT. mTORC2 is known to regulate the actin cytoskeleton, cell cycle progression and cellular survival (PMID: 18566586). Missense mutations of the MTOR gene occur in many tumors, notably in approximately 6% of clear cell renal cell carcinoma, 7.5% of lung adenocarcinomas, 5% of endometrial carcinomas and 4% of colon and rectal carcinomas (PMID: 24132290). Furthermore, various mTOR mutations have been characterized that cause increased MTOR pathway activation and increased sensitivity to rapamycin (PMID: 24631838, 24625776). Several case reports in the literature have reported extreme durable responses to rapamycin-analogue (rapalogue) therapies in patients with heavily pre-treated metastatic cancer and activating mTOR mutations (PMID: 24622468, 24625776). Additionally, two rapalogue mTOR inhibitors, everolimus and temsirolimus, are FDA-approved for the treatment of human cancer, and numerous compounds with alternative mechanisms of action are in various stages of development (PMID: 26299952).",,2017-08-09,,2475,MTOR,mechanistic target of rapamycin,True,ENST00000361445,NM_004958.3,FRAP1,RAFT1,FRAP2,FRAP,SKS,RAPT1,False,15268862,"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.",Current biology : CB,2018-07-27T20:04:00,14,14,1296-302,Sarbassov DD et al,,,2018-07-27T03:02:00,,24132290,Mutational landscape and significance across 12 major cancer types.,Nature,2018-10-17T20:13:00,502,7471,333-339,Kandoth C et al,doi: 10.1038/nature12634,,2018-10-17T03:39:00,,17510057,PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.,The Journal of biological chemistry,2018-07-06T20:07:00,282,27,20036-44,Wang L et al,,,0001-07-06,,12150925,mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.,Cell,2018-07-26T20:02:00,110,2,163-75,Kim DH et al,,,0001-07-26,,12718876,"GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.",Molecular cell,2018-04-01T20:03:00,11,4,895-904,Kim DH et al,,,2018-04-01T09:04:00,,19446321,DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.,Cell,2018-05-29T20:09:00,137,5,873-86,Peterson TR et al,doi: 10.1016/j.cell.2009.03.046,,0001-05-29,,12150926,"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.",Cell,2018-07-26T20:02:00,110,2,177-89,Hara K et al,,,0001-07-26,,17386266,PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.,Molecular cell,2018-03-23T20:07:00,25,6,903-15,Sancak Y et al,,,0001-03-23,,21157483,"mTOR: from growth signal integration to cancer, diabetes and ageing.",Nature reviews. Molecular cell biology,2018-01-01T20:11:00,12,True,21-35,Zoncu R et al,doi: 10.1038/nrm3025,,0001-01-01,,15718470,Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.,"Science (New York, N.Y.)",2018-02-18T20:05:00,307,5712,1098-101,Sarbassov DD et al,,,2018-02-18T01:01:00,,18566586,The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.,The EMBO journal,2018-07-23T20:08:00,27,14,1932-43,Facchinetti V et al,doi: 10.1038/emboj.2008.120,,0001-07-23,,15314020,Upstream and downstream of mTOR.,Genes &amp; development,2018-08-15T20:04:00,18,16,1926-45,Hay N et al,,,0001-08-15,,26299952,Toward rapamycin analog (rapalog)-based precision cancer therapy.,Acta pharmacologica Sinica,2018-10-01T20:15:00,36,10,1163-9,Meng LH et al,doi: 10.1038/aps.2015.68,,0001-10-01,,24631838,A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.,Cancer discovery,2018-05-01T20:14:00,4,5,554-63,Grabiner BC et al,doi: 10.1158/2159-8290.CD-13-0929,,0001-05-01,,24625776,Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.,Cancer discovery,2018-05-01T20:14:00,4,5,546-53,Wagle N et al,doi: 10.1158/2159-8290.CD-13-0353,,0001-05-01,,22500797,mTOR signaling in growth control and disease.,Cell,2018-04-13T20:12:00,149,2,274-93,Laplante M et al,doi: 10.1016/j.cell.2012.03.017,,0001-04-13,,16919458,"mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s.",Current biology : CB,2018-09-19T20:06:00,16,18,1865-70,Frias MA et al,,,0001-09-19,,24622468,Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-04-01T20:14:00,20,7,1955-64,Voss MH et al,doi: 10.1158/1078-0432.CCR-13-2345,,0001-04-01,
